Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.

BACKGROUND & AIMS Error catastrophe from an increase in mutation rate may be a possible mechanism of action of ribavirin in chronic hepatitis C (CHC). We sought to evaluate the mutagenic potential of ribavirin in vivo and to determine if conserved regions of hepatitis C virus (HCV) NS5B are mutated during ribavirin therapy. METHODS Thirty-one patients with CHC genotype 1 who participated in a randomized, placebo-controlled trial of ribavirin for 48 weeks were studied. After 48 weeks, patients on placebo were crossed-over to open-label ribavirin for 48 weeks. Viral RNA was extracted from paired, stored sera at day 0 and week 24 during the randomized phase and weeks 48, 52, and 72 during the cross-over phase. The entire NS5B region was sequenced and the mutation rates were calculated. RESULTS An increase in mutation rate was observed after 4 weeks (4.4 x 10(-2) vs 2.1 x 10(-3) per site/y, P = .02) but not after 24 weeks (4.0 x 10(-3) vs. 5.5 x 10(-3) per site/y, P = .1) in patients who crossed over to ribavirin. Similarly, during the randomized phase no increase in the number of mutations or the mutation rate was observed at week 24 between the ribavirin- and placebo-treated patients 6.6 vs 4.3 x 10(-3) per site/y, respectively (P = .4). No mutations were observed in conserved regions of NS5B. CONCLUSIONS Ribavirin therapy is associated with an early, transient increase in the mutation rate of HCV. Lethal mutagenesis and error catastrophe is unlikely to be the sole mechanism of action of ribavirin during therapy for CHC.

[1]  A. Randolph,et al.  Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. , 2010, The Cochrane database of systematic reviews.

[2]  M. Sugiyama,et al.  Detection of Anti-Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System , 2005, Journal of Clinical Microbiology.

[3]  N. Enomoto,et al.  Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. , 2005, Journal of hepatology.

[4]  R. Bartenschlager,et al.  Production of infectious hepatitis C virus in tissue culture from a cloned viral genome , 2005, Nature Medicine.

[5]  Julie K. Pfeiffer,et al.  Ribavirin Resistance in Hepatitis C Virus Replicon-Containing Cell Lines Conferred by Changes in the Cell Line or Mutations in the Replicon RNA , 2005, Journal of Virology.

[6]  A. Perelson,et al.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection , 2004, Nature.

[7]  A. Neumann,et al.  Antiviral action of ribavirin in chronic hepatitis C. , 2004, Gastroenterology.

[8]  M. Lai,et al.  Identification of a Ribavirin‐resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy , 2003, Hepatology.

[9]  M. Lai,et al.  Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. , 2003, Biochemistry.

[10]  J. Wu,et al.  Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. , 2003, Current drug targets. Infectious disorders.

[11]  Rong Liu,et al.  The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. , 2003, Virology.

[12]  E. Herrmann,et al.  Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon , 2003, Hepatology.

[13]  Deborah Chavez,et al.  Antiviral Effect and Virus-Host Interactions in Response to Alpha Interferon, Gamma Interferon, Poly(I)-Poly(C), Tumor Necrosis Factor Alpha, and Ribavirin in Hepatitis C Virus Subgenomic Replicons , 2003, Journal of Virology.

[14]  Raul Andino,et al.  Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirin. , 2002, Microbes and infection.

[15]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[16]  E. Schmidt,et al.  Viral RNA Mutations Are Region Specific and Increased by Ribavirin in a Full-Length Hepatitis C Virus Replication System , 2002, Journal of Virology.

[17]  I. W. Cheney,et al.  Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. , 2002, Virology.

[18]  C. Cameron,et al.  Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin* , 2001, The Journal of Biological Chemistry.

[19]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[20]  R. Lanford,et al.  Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes , 2001, Journal of Virology.

[21]  C. Cameron,et al.  RNA virus error catastrophe: Direct molecular test by using ribavirin , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Arnold,et al.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.

[23]  O. Weiland,et al.  The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. , 1998, The Journal of general virology.

[24]  M. Yanagi,et al.  Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. , 1998, Virology.

[25]  Ming Liu,et al.  Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. , 1998, Journal of immunology.

[26]  G. Davis,et al.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.

[27]  C. Rice,et al.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. , 1997, Science.

[28]  H. Thomas,et al.  Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. , 1996, Journal of hepatology.

[29]  H. Conjeevaram,et al.  Ribavirin as Therapy for Chronic Hepatitis C , 1995, Annals of Internal Medicine.

[30]  J. Drake.  Rates of spontaneous mutation among RNA viruses. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Purcell,et al.  Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Huggins.  Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.

[33]  D. Carson,et al.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. K. Lowe,et al.  Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. , 1977, Cancer research.

[35]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[36]  J. Pawlotsky,et al.  62 Is ribavirin antiviral effect in humans mediated by mutagenic properties resulting in error catastrophe , 2004 .